# Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

> **NCT00411528** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 185 (actual)

## Conditions studied

- Metastatic Hormone Refractory Prostate Cancer

## Interventions

- **DRUG:** Patupilone
- **DRUG:** prednisone
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00411528
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 185 (ACTUAL)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00411528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00411528, "Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00411528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*